Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04774081 · ClinicalTrials.gov registry record
Development of a Novel Method to Measure Insulin Sensitivity in Humans: A Pilot Study
A clinical trial of Insulin Sensitivity, sponsored by Pennington Biomedical Research Center.
- Completed
- Registry status
- 13
- Enrollment target
- 1
- Study location
NCT04774081: Completed study of Insulin Sensitivity, sponsored by Pennington Biomedical Research Center.
NCT04774081 is a study of Insulin Sensitivity that has completed, run by Pennington Biomedical Research Center. The registered enrollment target is 13 participants, below the 72-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04774081, a study of Insulin Sensitivity, has completed, sponsored by Pennington Biomedical Research Center.
- COMPLETED
- Registry status
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will determine whether the ratio between 24h C-peptide urinary excretion rate and average 24h circulating glucose represent a good correlate of what is measured by the gold standard, i.e. M (glucose disposal rate) from a euglycemic-hyperinsulinemic clamp
Conditions Studied
Interventions
- DEVICE 24h Continuous glucose monitoring and urinary C-peptide collection
Study Locations (1)
Louisiana
- Pennington Biomedical Research Center - Baton Rouge
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-02-08 |
| Est. Completion | 2022-02-21 |
What the finished NCT04774081 record still lists
NCT04774081 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 72-participant average among 29 other Insulin Sensitivity trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Insulin Sensitivity appearing as the primary indexed condition, and to 1 intervention - of which 24h Continuous glucose monitoring and urinary C-peptide collection is the first listed.
NCT04774081 reports a single indexed study location in Louisiana.
Frequently Asked Questions
What is clinical trial NCT04774081 about?
NCT04774081 is a clinical study titled "Development of a Novel Method to Measure Insulin Sensitivity in Humans: A Pilot Study". This study will determine whether the ratio between 24h C-peptide urinary excretion rate and average 24h circulating glucose represent a good correlate of what is measured by the gold standard, i.e. M (glucose disposal rate) from a euglycemic-hyperinsulinemic clamp
What is the current status of trial NCT04774081?
This trial is currently completed. The enrollment target is 13 participants. The study started on 2021-02-08. Estimated completion is 2022-02-21.
What conditions does trial NCT04774081 study?
This clinical trial studies the following conditions: Insulin Sensitivity.
What interventions are being tested in trial NCT04774081?
The interventions under investigation include: 24h Continuous glucose monitoring and urinary C-peptide collection (DEVICE).
Who is sponsoring clinical trial NCT04774081?
This trial is sponsored by Pennington Biomedical Research Center, which has 258 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04774081 being conducted?
This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Sensitivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04774081's enrollment target sits among peer trials
13 26th of 29 higher than 4 of 29 other Insulin Sensitivity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Sensitivity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Countermeasures to Circadian Misalignment
RECRUITING · NA
-
Effect of Pulsatile Hormone Administration on Insulin Action
RECRUITING · NA
-
Mechanisms of Ultrasound Neuromodulation Effects in Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI